8-K: Serina Therapeutics Reports Q2 2026 Results, Advances SER-252 Trial

Serina Therapeutics announced second quarter 2026 financial results, reporting progress in its SER-252 clinical trial and a strategic partnership, while also detailing operating expenses and net loss.

Summary

• Serina Therapeutics reported its financial results for the second quarter ended June 30, 2026.
• Enrollment and dosing for Cohort 1 of the SER-252 Phase 1b registrational study were completed in July 2026, ahead of the previously guided end of Q3 2026.
• Top-line data from the single-ascending-dose arm of the SER-252 study are targeted for the first half of 2027.
• The company entered into a development partnership with Gannet BioChem in June 2026 to support process development, scale-up, and manufacturing for SER-252.
• Farrell Simon, Pharm.D., was appointed to the Board of Directors in July 2026.
• Operating expenses for Q2 2026 were $6.8 million, an increase from $5.7 million in Q2 2025.
• Research and Development (R&D) expenses were $3.8 million in Q2 2026, up from $3.2 million in Q2 2025.
• General and Administrative (G&A) expenses were $3.0 million in Q2 2026, up from $2.5 million in Q2 2025.
• The net loss attributable to Serina common shareholders for Q2 2026 was $8.9 million, or $(0.55) per share, compared to a net loss of $6.6 million, or $(0.66) per share, in Q2 2025.
• Cash and cash equivalents totaled $23.0 million as of June 30, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive report, highlighting progress in clinical trials and strategic partnerships, but tempered by continued net losses and the inherent risks of clinical-stage biotechnology.

Positives

• Completion of enrollment and dosing in Cohort 1 of the SER-252 Phase 1b registrational study in July 2026, ahead of schedule.
• Appointment of Farrell Simon, Pharm.D., to the Board of Directors, bringing valuable experience in commercial strategy and business development.
• Establishment of a development partnership with Gannet BioChem to enhance process development, scale-up, and manufacturing capabilities for SER-252.
• The net loss per share improved to $(0.55) in Q2 2026 from $(0.66) in Q2 2025, indicating a reduction in per-share loss.
• Cash and cash equivalents increased significantly to $23.0 million as of June 30, 2026, from $3.056 million as of December 31, 2025, providing enhanced liquidity.

Negatives

• Total operating expenses increased to $6.8 million in Q2 2026 from $5.7 million in Q2 2025.
• Research and Development expenses increased by $0.6 million to $3.8 million in Q2 2026 compared to Q2 2025.
• General and Administrative expenses increased by $0.5 million to $3.0 million in Q2 2026 compared to Q2 2025, primarily due to legal expenses.
• The net loss attributable to Serina common shareholders widened to $8.9 million in Q2 2026 from $6.6 million in Q2 2025.
• Other income, net decreased to $0.4 million in Q2 2026 from $0.9 million in Q2 2025.

Risks

• The inherent uncertainties in research and development, including the ability to meet anticipated clinical endpoints and achieve regulatory approvals.
• The possibility of unfavorable new clinical data or further analyses of existing clinical data for SER-252.
• Regulatory authorities may not be satisfied with the design or results of clinical studies.
• The company's ability to continue as a going concern is subject to future financing and successful clinical development.
• Competitive developments in the treatment of Parkinson's disease and other neurological indications.
• Potential delays in clinical trial commencement, completion, or regulatory submission and approval dates.
• The risk that SER-252 may not demonstrate a differentiated product profile or commercial success.

Future Outlook

Top-line data from the single-ascending-dose arm of the SER-252 study are targeted for the first half of 2027. The company's near-term priority is disciplined clinical execution and generating data to evaluate SER-252's potential.

Management Comments

• "We continued on our strategic plan, completing enrollment and dosing in Cohort 1 of the SER-252 registrational study ahead of our prior guidance," said Steve Ledger, Chief Executive Officer of Serina.
• "Completion of Cohort 1 progresses the program to its next protocol-defined safety review and dose-escalation decision as we expect top-line data from the single-ascending-dose arm in the first half of 2027."
• "We also strengthened the capabilities supporting SER-252 and the broader POZ Platform through our development partnership with Gannet BioChem and the appointment of Farrell Simon to our Board."
• "Our near-term priority remains disciplined clinical execution and generating the data needed to evaluate whether SER-252 can deliver a differentiated product profile for patients with advanced Parkinsons disease, where a high unmet need for more tolerable therapies continues to exist."

Industry Context

StockSavvy.ai notes that Serina Therapeutics operates in the highly competitive and capital-intensive clinical-stage biotechnology sector, focusing on neurological diseases. The company's progress with SER-252 and its POZ Platform technology aligns with industry trends towards developing more targeted and tolerable therapies for conditions with significant unmet needs, such as Parkinson's disease.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The company's continued progress in clinical trials and strategic partnerships may be viewed positively, but the widening net loss and ongoing need for financing present risks.
• Employees: Increased R&D and G&A expenses suggest continued investment in personnel and operations, potentially leading to growth.
• Patients: Advancement of SER-252 offers potential for new, more tolerable therapies for Parkinson's disease.
• Creditors: The company's liquidity has improved significantly, reducing short-term concerns.

Next Steps

• Proceed to the next protocol-defined safety review and dose-escalation decision for SER-252.
• Generate top-line data from the single-ascending-dose arm of the SER-252 study in the first half of 2027.
• Continue disciplined clinical execution for SER-252.
• Evaluate whether SER-252 can deliver a differentiated product profile for patients with advanced Parkinson's disease.
• Advance additional applications of the POZ platform via out-licensing, co-development, or other partnership arrangements.

Key Dates

Recommendation

The company is making progress in its clinical development and strategic partnerships, which are positive indicators. However, the increasing net losses, the long timeline to potential data readout, and the inherent risks in clinical-stage biotechnology warrant a cautious approach. The significant increase in cash provides a buffer, but the path to profitability remains uncertain, making 'hold' the most prudent recommendation until more definitive clinical data emerges.

Keywords

SER-252, Parkinson's disease, POZ Platform, clinical trial, biotechnology, drug optimization, apomorphine therapy, Phase 1b study